Deals in Depth: March 2009
Executive Summary
Our monthly overview of dealmaking in the biopharmaceutical, medical device and in vitro diagnostics industries. March 2009 dealmaking highlights: BMS' worldwide ex-Japanese license to Nissan/Teijin's CV candidate NTC801 topped the alliance list in terms of potential deal value at $210mm. The remaining pharma alliances for March didn't even surpass $50mm in pre-commercial value. In M&As, the Big Pharma mega merger of Merck and Schering-Plough was the biggest news, in a deal valued around $42bn. Pharmaceutical financings were down by about $100mm compared with February, and Early VC rounds made up the majority of the $406mm raised. Funding for device firms, on the other hand, was up from last month to $297mm thanks to a strong showing of late venture financings.
You may also be interested in...
Finance Watch: CureVac’s IPO Is Ready For Launch
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
US FDA's Hahn Promotes Provider Role In Boosting Public Confidence In COVID-19 Products
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.
Medtronic Adds Smart Insulin Pen By Acquiring Companion Medical
The deal is part of Medtronic's ongoing strategy to revive its diabetes business with technology that simplifies insulin delivery.
Need a specific report? 1000+ reports available
Buy Reports